S&P 500 Futures
(0.11%) 5 137.00 points
Dow Jones Futures
(0.05%) 38 460 points
Nasdaq Futures
(0.19%) 17 880 points
Oil
(-0.23%) $83.66
Gas
(1.82%) $1.958
Gold
(0.10%) $2 349.60
Silver
(0.44%) $27.66
Platinum
(1.49%) $935.85
USD/EUR
(-0.09%) $0.934
USD/NOK
(-0.21%) $11.00
USD/GBP
(-0.21%) $0.799
USD/RUB
(1.27%) $93.04

リアルタイムの更新: GSK plc [GS7.DE]

取引所: XETRA セクター: Healthcare 産業: Drug Manufacturers—General
最終更新日時19 7月 2022 @ 00:35

25.00% 20.60

Live Chart Being Loaded With Signals

Commentary (19 7月 2022 @ 00:35):

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally...

Stats
本日の出来高 290 930
平均出来高 0
時価総額 0.00
EPS €0.230 ( 2022-06-29 )
Last Dividend €0.163 ( 2022-08-18 )
Next Dividend €0 ( N/A )
P/E 17.31
ATR14 €0 (0.00%)

GSK plc 相関

10 最も正の相関
10 最も負の相関

知っていましたか?

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

GSK plc 財務諸表

Annual 2021
収益: €34.11B
総利益: €22.51B (65.99 %)
EPS: €1.102
FY 2021
収益: €34.11B
総利益: €22.51B (65.99 %)
EPS: €1.102
FY 2020
収益: €34.10B
総利益: €22.40B (65.68 %)
EPS: €1.426
FY 2019
収益: €33.75B
総利益: €21.89B (64.85 %)
EPS: €1.158

Financial Reports:

No articles found.

GSK plc Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€0.163
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

GSK plc Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.49 - good (84.92%) | Divividend Growth Potential Score: 4.03 - Potential for dividend initiation, but uncertain (19.30%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend €0.140 2004-02-18
Last Dividend €0.163 2022-08-18
Next Dividend €0 N/A
Payout Date 2022-10-06
Next Payout Date N/A
# dividends 75 --
Total Paid Out €12.75 --
Avg. Dividend % Per Year 0.00% --
Score 4.13 --
Div. Sustainability Score 8.49
Div.Growth Potential Score 4.03
Div. Directional Score 6.26 --
Next Divdend (Est)
(2024-06-28)
€0 Estimate 0.00 %
Dividend Stability
0.19 Bad
Dividend Score
4.13
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for XETRA

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
H5E.DE No Dividend Player 2023-07-10 Annually 0 0.00%
RAA.DE Ex Dividend Knight 2023-05-11 Annually 0 0.00%
BPFG.F Ex Dividend Junior 2023-09-12 Semi-Annually 0 0.00%
ITU.DE Ex Dividend Knight 2023-10-06 Quarterly 0 0.00%
SYT.DE Ex Dividend Junior 2023-05-05 Annually 0 0.00%
DAR.DE No Dividend Player 2023-07-03 Annually 0 0.00%
M4N.DE Ex Dividend Junior 2023-06-07 Sporadic 0 0.00%
3T70.F Ex Dividend Knight 2023-08-31 Quarterly 0 0.00%
VNA.F Ex Dividend Junior 2023-05-18 Annually 0 0.00%
ERCG.DE Ex Dividend Junior 2023-09-28 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.1491.5007.0110.00[0 - 0.5]
returnOnAssetsTTM0.06441.2007.859.42[0 - 0.3]
returnOnEquityTTM0.3441.5007.2910.00[0.1 - 1]
payoutRatioTTM0.785-1.0002.15-2.15[0 - 1]
currentRatioTTM0.7890.800-1.055-0.844[1 - 3]
quickRatioTTM0.1830.800-3.63-2.90[0.8 - 2.5]
cashRatioTTM0.1811.500-0.108-0.162[0.2 - 2]
debtRatioTTM0.306-1.5004.91-7.36[0 - 0.6]
interestCoverageTTM7.031.0008.518.51[3 - 30]
operatingCashFlowPerShareTTM1.9982.009.3310.00[0 - 30]
freeCashFlowPerShareTTM1.2612.009.3710.00[0 - 20]
debtEquityRatioTTM1.606-1.5003.58-5.37[0 - 2.5]
grossProfitMarginTTM0.6601.0002.342.34[0.2 - 0.8]
operatingProfitMarginTTM0.1621.0008.778.77[0.1 - 0.6]
cashFlowToDebtRatioTTM0.3291.0009.289.28[0.2 - 2]
assetTurnoverTTM0.4310.800-0.458-0.367[0.5 - 2]
Total Score8.49

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM13.771.0008.710[1 - 100]
returnOnEquityTTM0.3442.508.2610.00[0.1 - 1.5]
freeCashFlowPerShareTTM1.2612.009.5810.00[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM1.9982.009.3310.00[0 - 30]
payoutRatioTTM0.7851.5002.15-2.15[0 - 1]
pegRatioTTM-0.3261.500-5.510[0.5 - 2]
operatingCashFlowSalesRatioTTM0.2331.0006.670[0.1 - 0.5]
Total Score4.03

GSK plc

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。